{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:36:24Z","timestamp":1769744184673,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006468","name":"KU | College of Medicine, Korea University","doi-asserted-by":"publisher","award":["NC"],"award-info":[{"award-number":["NC"]}],"id":[{"id":"10.13039\/501100006468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006468","name":"KU | College of Medicine, Korea University","doi-asserted-by":"publisher","award":["NC"],"award-info":[{"award-number":["NC"]}],"id":[{"id":"10.13039\/501100006468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006468","name":"KU | College of Medicine, Korea University","doi-asserted-by":"publisher","award":["NC"],"award-info":[{"award-number":["NC"]}],"id":[{"id":"10.13039\/501100006468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006468","name":"KU | College of Medicine, Korea University","doi-asserted-by":"publisher","award":["NC"],"award-info":[{"award-number":["NC"]}],"id":[{"id":"10.13039\/501100006468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006468","name":"KU | College of Medicine, Korea University","doi-asserted-by":"publisher","award":["NC"],"award-info":[{"award-number":["NC"]}],"id":[{"id":"10.13039\/501100006468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006468","name":"KU | College of Medicine, Korea University","doi-asserted-by":"publisher","award":["NC"],"award-info":[{"award-number":["NC"]}],"id":[{"id":"10.13039\/501100006468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006468","name":"KU | College of Medicine, Korea University","doi-asserted-by":"publisher","award":["NC"],"award-info":[{"award-number":["NC"]}],"id":[{"id":"10.13039\/501100006468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aberrant activation of fibroblast growth factor receptor (FGFR) signalling contributes to progression and metastasis of many types of cancers including breast cancer. Accordingly, FGFR targeted tyrosine kinase inhibitors (TKIs) are currently under development. However, the efficacy of FGFR TKIs in the bone microenvironment where breast cancer cells most frequently metastasize and also where FGFR is biologically active, has not been clearly investigated. We investigated the FGFR-mediated interactions among cancer and the bone microenvironment stromal cells (osteoblasts and osteoclasts), and also the effects of FGFR inhibition in bone metastasis. We showed that addition of culture supernatant from the MDA-MB-134-VI <jats:italic>FGFR<\/jats:italic>-amplified breast cancer cells-activated FGFR siganalling in osteoblasts, including increased expression of RANKL, M-CSF, and osteoprotegerin (OPG). Further <jats:italic>in vitro<\/jats:italic> analyses showed that AZD4547, an FGFR TKI currently in clinical trials for breast cancer, decreased RANKL and M-CSF, and subsequently RANKL and M-CSF-dependent osteoclastogenesis of murine bone marrow monocytes. Moreover, AZD4547 suppressed osteoclastogenesis and tumor-induced osteolysis in an orthotopic breast cancer bone metastasis mouse model using FGFR non-amplified MDA-MB-231 cells. Collectively, our results support that FGFR inhibitors inhibit the bone microenvironment stromal cells including osteoblasts and osteoclasts, and effectively suppress both tumor and stromal compartments of bone metastasis.<\/jats:p>","DOI":"10.1038\/s41598-019-45278-w","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T12:04:56Z","timestamp":1560945896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Selective FGFR inhibitor AZD4547 suppresses RANKL\/M-CSF\/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment"],"prefix":"10.1038","volume":"9","author":[{"given":"Jinho","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-0555","authenticated-orcid":false,"given":"Yoon Ji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Yeon","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ukhyun","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-5096","authenticated-orcid":false,"given":"Serk In","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeul Hong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyong Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"45278_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature05610","volume":"446","author":"C Greenman","year":"2007","unstructured":"Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153\u2013158, https:\/\/doi.org\/10.1038\/nature05610 (2007).","journal-title":"Nature"},{"key":"45278_CR2","doi-asserted-by":"publisher","first-page":"D165","DOI":"10.2741\/Klint","volume":"4","author":"P Klint","year":"1999","unstructured":"Klint, P. & Claesson-Welsh, L. Signal transduction by fibroblast growth factor receptors. Frontiers in bioscience: a journal and virtual library 4, D165\u2013177 (1999).","journal-title":"Frontiers in bioscience: a journal and virtual library"},{"key":"45278_CR3","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.1158\/1078-0432.ccr-05-0282","volume":"11","author":"J Martinez-Torrecuadrada","year":"2005","unstructured":"Martinez-Torrecuadrada, J. et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clinical cancer research: an official journal of the American Association for Cancer Research 11, 6280\u20136290, https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-0282 (2005).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"45278_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.tips.2012.07.001","volume":"33","author":"G Liang","year":"2012","unstructured":"Liang, G., Liu, Z., Wu, J., Cai, Y. & Li, X. Anticancer molecules targeting fibroblast growth factor receptors. Trends in pharmacological sciences 33, 531\u2013541, https:\/\/doi.org\/10.1016\/j.tips.2012.07.001 (2012).","journal-title":"Trends in pharmacological sciences"},{"key":"45278_CR5","first-page":"219","volume":"7","author":"C Theillet","year":"1993","unstructured":"Theillet, C. et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes, chromosomes &. cancer 7, 219\u2013226 (1993).","journal-title":"cancer"},{"key":"45278_CR6","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/bcr1665","volume":"9","author":"S Elbauomy Elsheikh","year":"2007","unstructured":"Elbauomy Elsheikh, S. et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast cancer research: BCR 9, R23, https:\/\/doi.org\/10.1186\/bcr1665 (2007).","journal-title":"Breast cancer research: BCR"},{"key":"45278_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.gene.2006.04.028","volume":"379","author":"RA Jackson","year":"2006","unstructured":"Jackson, R. A., Nurcombe, V. & Cool, S. M. Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis. Gene 379, 79\u201391, https:\/\/doi.org\/10.1016\/j.gene.2006.04.028 (2006).","journal-title":"Gene"},{"key":"45278_CR8","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1359\/jbmr.2001.16.11.2074","volume":"16","author":"D Chikazu","year":"2001","unstructured":"Chikazu, D. et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand\/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 16, 2074\u20132081, https:\/\/doi.org\/10.1359\/jbmr.2001.16.11.2074 (2001).","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"45278_CR9","doi-asserted-by":"publisher","first-page":"6213s","DOI":"10.1158\/1078-0432.ccr-06-1007","volume":"12","author":"TA Guise","year":"2006","unstructured":"Guise, T. A. et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical cancer research: an official journal of the American Association for Cancer Research 12, 6213s\u20136216s, https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-1007 (2006).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"45278_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh, M. & Nakagama, H. FGF receptors: cancer biology and therapeutics. Medicinal research reviews 34, 280\u2013300, https:\/\/doi.org\/10.1002\/med.21288 (2014).","journal-title":"Medicinal research reviews"},{"key":"45278_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-245","volume":"10","author":"ZY Chen","year":"2012","unstructured":"Chen, Z. Y. et al. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. Journal of translational medicine 10, 245, https:\/\/doi.org\/10.1186\/1479-5876-10-245 (2012).","journal-title":"Journal of translational medicine"},{"key":"45278_CR12","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1158\/1078-0432.ccr-13-0190","volume":"19","author":"F Andre","year":"2013","unstructured":"Andre, F. et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 19, 3693\u20133702, https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-0190 (2013).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"45278_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1078-0432.ccr-12-2885","volume":"19","author":"E Angevin","year":"2013","unstructured":"Angevin, E. et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 19, 1257\u20131268, https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-2885 (2013).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"45278_CR14","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1158\/1078-0432.ccr-13-1550","volume":"19","author":"PG Corn","year":"2013","unstructured":"Corn, P. G., Wang, F., McKeehan, W. L. & Navone, N. Targeting fibroblast growth factor pathways in prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 19, 5856\u20135866, https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-1550 (2013).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"45278_CR15","doi-asserted-by":"publisher","first-page":"252ra122","DOI":"10.1126\/scitranslmed.3009332","volume":"6","author":"X Wan","year":"2014","unstructured":"Wan, X. et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Science translational medicine 6, 252ra122, https:\/\/doi.org\/10.1126\/scitranslmed.3009332 (2014).","journal-title":"Science translational medicine"},{"key":"45278_CR16","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.ccr-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks, A. N., Kilgour, E. & Smith, P. D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 1855\u20131862, https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-0699 (2012).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"45278_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/0008-5472.can-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine, P. R. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer research 72, 2045\u20132056, https:\/\/doi.org\/10.1158\/0008-5472.can-11-3034 (2012).","journal-title":"Cancer research"},{"key":"45278_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000358640","volume":"33","author":"L Liu","year":"2014","unstructured":"Liu, L. et al. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 33, 633\u2013645, https:\/\/doi.org\/10.1159\/000358640 (2014).","journal-title":"Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology"},{"key":"45278_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1210\/edrv.19.1.0323","volume":"19","author":"TA Guise","year":"1998","unstructured":"Guise, T. A. & Mundy, G. R. Cancer and bone. Endocrine reviews 19, 18\u201354, https:\/\/doi.org\/10.1210\/edrv.19.1.0323 (1998).","journal-title":"Endocrine reviews"},{"key":"45278_CR20","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","volume":"80","author":"GR Mundy","year":"1997","unstructured":"Mundy, G. R. Mechanisms of bone metastasis. Cancer 80, 1546\u20131556 (1997).","journal-title":"Cancer"},{"key":"45278_CR21","first-page":"570","volume":"2","author":"TA Guise","year":"2002","unstructured":"Guise, T. A. The vicious cycle of bone metastases. Journal of musculoskeletal & neuronal interactions 2, 570\u2013572 (2002).","journal-title":"Journal of musculoskeletal & neuronal interactions"},{"key":"45278_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1023\/A:1010015309973","volume":"2","author":"GR Mundy","year":"2001","unstructured":"Mundy, G. R. et al. Growth regulatory factors and bone. Reviews in endocrine & metabolic disorders 2, 105\u2013115 (2001).","journal-title":"Reviews in endocrine & metabolic disorders"},{"key":"45278_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2010.227","volume":"7","author":"LJ Suva","year":"2011","unstructured":"Suva, L. J., Washam, C., Nicholas, R. W. & Griffin, R. J. Bone metastasis: mechanisms and therapeutic opportunities. Nature reviews. Endocrinology 7, 208\u2013218, https:\/\/doi.org\/10.1038\/nrendo.2010.227 (2011).","journal-title":"Nature reviews. Endocrinology"},{"key":"45278_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jnci.2012.06.002","volume":"24","author":"HA Azim","year":"2012","unstructured":"Azim, H. A., Kamal, N. S. & Azim, H. A. Jr. Bone metastasis in breast cancer: the story of RANK-ligand. Journal of the Egyptian National Cancer Institute 24, 107\u2013114, https:\/\/doi.org\/10.1016\/j.jnci.2012.06.002 (2012).","journal-title":"Journal of the Egyptian National Cancer Institute"},{"key":"45278_CR25","doi-asserted-by":"publisher","first-page":"e0185736","DOI":"10.1371\/journal.pone.0185736","volume":"12","author":"K Aukes","year":"2017","unstructured":"Aukes, K. et al. Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions. PloS one 12, e0185736, https:\/\/doi.org\/10.1371\/journal.pone.0185736 (2017).","journal-title":"PloS one"},{"key":"45278_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/jco.2012.43.8622","volume":"31","author":"HR Kim","year":"2013","unstructured":"Kim, H. R. et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31, 731\u2013737, https:\/\/doi.org\/10.1200\/jco.2012.43.8622 (2013).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"45278_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.oraloncology.2013.01.006","volume":"49","author":"RJ Young","year":"2013","unstructured":"Young, R. J. et al. Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. Oral oncology 49, 576\u2013581, https:\/\/doi.org\/10.1016\/j.oraloncology.2013.01.006 (2013).","journal-title":"Oral oncology"},{"key":"45278_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","volume":"43","author":"K Freier","year":"2007","unstructured":"Freier, K. et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral oncology 43, 60\u201366, https:\/\/doi.org\/10.1016\/j.oraloncology.2006.01.005 (2007).","journal-title":"Oral oncology"},{"key":"45278_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/his.12115","volume":"63","author":"NC Lehnen","year":"2013","unstructured":"Lehnen, N. C. et al. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology 63, 157\u2013166, https:\/\/doi.org\/10.1111\/his.12115 (2013).","journal-title":"Histopathology"},{"key":"45278_CR30","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.can-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner, N. et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer research 70, 2085\u20132094, https:\/\/doi.org\/10.1158\/0008-5472.can-09-3746 (2010).","journal-title":"Cancer research"},{"key":"45278_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1756-9966-31-103","volume":"31","author":"E Brunello","year":"2012","unstructured":"Brunello, E. et al. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. Journal of experimental & clinical cancer research: CR 31, 103, https:\/\/doi.org\/10.1186\/1756-9966-31-103 (2012).","journal-title":"Journal of experimental & clinical cancer research: CR"},{"key":"45278_CR32","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1172\/jci113490","volume":"81","author":"E Canalis","year":"1988","unstructured":"Canalis, E., Centrella, M. & McCarthy, T. Effects of basic fibroblast growth factor on bone formation in vitro. The Journal of clinical investigation 81, 1572\u20131577, https:\/\/doi.org\/10.1172\/jci113490 (1988).","journal-title":"The Journal of clinical investigation"},{"key":"45278_CR33","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1016\/S0021-9258(18)53361-5","volume":"268","author":"MM Hurley","year":"1993","unstructured":"Hurley, M. M. et al. Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. The Journal of biological chemistry 268, 5588\u20135593 (1993).","journal-title":"The Journal of biological chemistry"},{"key":"45278_CR34","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1016\/S0021-9258(17)37121-1","volume":"269","author":"MM Hurley","year":"1994","unstructured":"Hurley, M. M., Abreu, C., Gronowicz, G., Kawaguchi, H. & Lorenzo, J. Expression and regulation of basic fibroblast growth factor mRNA levels in mouse osteoblastic MC3T3-E1 cells. The Journal of biological chemistry 269, 9392\u20139396 (1994).","journal-title":"The Journal of biological chemistry"},{"key":"45278_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ijc.23422","volume":"123","author":"MP Valta","year":"2008","unstructured":"Valta, M. P. et al. FGF-8 is involved in bone metastasis of prostate cancer. International journal of cancer 123, 22\u201331, https:\/\/doi.org\/10.1002\/ijc.23422 (2008).","journal-title":"International journal of cancer"},{"key":"45278_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2353\/ajpath.2010.100070","volume":"177","author":"A Johansson","year":"2010","unstructured":"Johansson, A. et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. The American journal of pathology 177, 1031\u20131041, https:\/\/doi.org\/10.2353\/ajpath.2010.100070 (2010).","journal-title":"The American journal of pathology"},{"key":"45278_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.taap.2011.04.019","volume":"254","author":"M Nurmio","year":"2011","unstructured":"Nurmio, M. et al. Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. Toxicology and applied pharmacology 254, 267\u2013279, https:\/\/doi.org\/10.1016\/j.taap.2011.04.019 (2011).","journal-title":"Toxicology and applied pharmacology"},{"key":"45278_CR38","doi-asserted-by":"publisher","first-page":"e78881","DOI":"10.1371\/journal.pone.0078881","volume":"8","author":"HM Nguyen","year":"2013","unstructured":"Nguyen, H. M. et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PloS one 8, e78881, https:\/\/doi.org\/10.1371\/journal.pone.0078881 (2013).","journal-title":"PloS one"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45278-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45278-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45278-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:31:30Z","timestamp":1671273090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45278-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45278"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45278-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"assertion":[{"value":"15 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8726"}}